WO2006076288A3 - Dna constructs for long-term expression of intravascularly injected naked dna - Google Patents

Dna constructs for long-term expression of intravascularly injected naked dna Download PDF

Info

Publication number
WO2006076288A3
WO2006076288A3 PCT/US2006/000668 US2006000668W WO2006076288A3 WO 2006076288 A3 WO2006076288 A3 WO 2006076288A3 US 2006000668 W US2006000668 W US 2006000668W WO 2006076288 A3 WO2006076288 A3 WO 2006076288A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna molecules
expressed
dna
long
term expression
Prior art date
Application number
PCT/US2006/000668
Other languages
French (fr)
Other versions
WO2006076288A2 (en
Inventor
Lewis T Williams
Hongbing Zhang
Stephen Doberstein
Ernestine Lee
Original Assignee
Five Prime Therapeutics Inc
Lewis T Williams
Hongbing Zhang
Stephen Doberstein
Ernestine Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Lewis T Williams, Hongbing Zhang, Stephen Doberstein, Ernestine Lee filed Critical Five Prime Therapeutics Inc
Publication of WO2006076288A2 publication Critical patent/WO2006076288A2/en
Publication of WO2006076288A3 publication Critical patent/WO2006076288A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Hydrodynamic intravascular injection of recombinant DNA molecules that can be expressed in the liver provides sustained and/or high-level expression of genes in a simple, safe, inexpensive, and reproducible fashion. These DNA molecules include a first sequence with the promoter of a liver-expressed gene operably linked to a second sequence encoding a protein of interest. The DNA molecules can be expressed in vivo to produce functionally active proteins. Methods of the invention provide tools to study these proteins in vivo and therapeutic applications for the expressed DNA molecules.
PCT/US2006/000668 2005-01-11 2006-01-10 Dna constructs for long-term expression of intravascularly injected naked dna WO2006076288A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64260405P 2005-01-11 2005-01-11
US60/642,604 2005-01-11

Publications (2)

Publication Number Publication Date
WO2006076288A2 WO2006076288A2 (en) 2006-07-20
WO2006076288A3 true WO2006076288A3 (en) 2006-12-21

Family

ID=36498725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/000668 WO2006076288A2 (en) 2005-01-11 2006-01-10 Dna constructs for long-term expression of intravascularly injected naked dna

Country Status (1)

Country Link
WO (1) WO2006076288A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101838329A (en) 2009-03-18 2010-09-22 嘉和生物药业有限公司 Anti-angiogenesis fusion protein
TR201900368T4 (en) 2010-05-04 2019-02-21 Five Prime Therapeutics Inc Antibodies that bind to Csf1r.
WO2012006027A1 (en) 2010-06-28 2012-01-12 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same
EP2640377B1 (en) 2010-11-15 2018-12-26 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
CA2824805A1 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
CA2871445C (en) 2012-05-11 2020-07-07 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN107759690A (en) 2012-08-31 2018-03-06 戊瑞治疗有限公司 With the method for the Antybody therapy symptom for combining the acceptor of colony stimulating factor 1 (CSF1R)
SG11201508878WA (en) 2013-05-01 2015-11-27 Five Prime Therapeutics Inc Methods of treating cancer
US9775881B2 (en) 2013-05-23 2017-10-03 Five Prime Therapeutics, Inc. Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI711463B (en) 2014-10-29 2020-12-01 美商戊瑞治療有限公司 Combination therapy for cancer
AU2015369854B2 (en) 2014-12-22 2021-07-01 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
CN114681608A (en) 2015-04-13 2022-07-01 戊瑞治疗有限公司 Combination cancer therapy
RU2021107536A (en) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN THE TREATMENT OF CANCER
CN115975044A (en) 2016-04-25 2023-04-18 戊瑞治疗有限公司 NOPE for the treatment of pathological muscle loss and weakness
EP3624837A1 (en) 2017-05-16 2020-03-25 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
EP4087874A1 (en) 2020-01-06 2022-11-16 HiFiBiO (HK) Limited Anti-tnfr2 antibody and uses thereof
MX2022008421A (en) 2020-01-07 2022-09-23 Hifibio Hk Ltd Anti-galectin-9 antibody and uses thereof.
WO2022033419A2 (en) 2020-08-10 2022-02-17 Shanghai Xbh Biotechnology Co., Ltd. Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
TW202306993A (en) 2021-05-14 2023-02-16 美商建南德克公司 Agonists of trem2
WO2024006975A1 (en) 2022-07-01 2024-01-04 Bristol-Myers Squibb Company Methods for antibody humanization
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
WO2024020579A1 (en) 2022-07-22 2024-01-25 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
WO2024040216A2 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. Anti-ccr8 antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002056A1 (en) * 1989-08-09 1991-02-21 Transgene S.A. Cell lineages expressing a biologically active ix factor
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US20020041873A1 (en) * 2000-08-18 2002-04-11 Giorgio Senaldi Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
WO2003013536A2 (en) * 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for treatment of cancer using irinotecan based on ugt1a1
WO2004009834A2 (en) * 2001-07-21 2004-01-29 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
WO2005026718A1 (en) * 2003-08-28 2005-03-24 Five Prime Therapeutics, Inc. Stem cell libraries

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002056A1 (en) * 1989-08-09 1991-02-21 Transgene S.A. Cell lineages expressing a biologically active ix factor
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US20020041873A1 (en) * 2000-08-18 2002-04-11 Giorgio Senaldi Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
WO2004009834A2 (en) * 2001-07-21 2004-01-29 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
WO2003013536A2 (en) * 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for treatment of cancer using irinotecan based on ugt1a1
WO2005026718A1 (en) * 2003-08-28 2005-03-24 Five Prime Therapeutics, Inc. Stem cell libraries

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 22 September 2000 (2000-09-22), "Homo sapiens cDNA clone:GKCDME11, 5'end, expressed in human hepatocellular carcinoma.", XP002384337, retrieved from EBI accession no. EM_PRO:AV685870 Database accession no. AV685870 *
DATABASE Geneseq [online] 3 June 2004 (2004-06-03), "Human protein encoding cDNA SEQ ID NO:188.", XP002384336, retrieved from EBI accession no. GSN:ADM87095 Database accession no. ADM87095 *
DATABASE Geneseq [online] 4 December 2003 (2003-12-04), "Human UGT1A1 gene sequence SEQ ID NO:662.", XP002384335, retrieved from EBI accession no. GSN:ADB87938 Database accession no. ADB87938 *
XU XIANG-RU ET AL: "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 26, 18 December 2001 (2001-12-18), pages 15089 - 15094, XP002384309, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006076288A2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
WO2006076288A3 (en) Dna constructs for long-term expression of intravascularly injected naked dna
WO2008048545A3 (en) Molecules with reduced half-lives, compositions and uses thereof
WO2005079532A3 (en) Methods and compositions for enhancing risc activity in vitro and in vivo
PH12016500081A1 (en) Immunoglobulin variants and uses thereof
WO2005044853A3 (en) Anti-vegf antibodies
WO2005012359A3 (en) Anti-vegf antibodies
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2006021894A3 (en) Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
AR072680A1 (en) AXMI-115 AXMI-113 AXMI-005 AXMI-163 AND AXMI-184 INSECTED PROTEINS AND METHODS OF THE SAME USE
UA113609C2 (en) ANTIGENCY BINDING PROTEIN Binding HUMAN IL-23
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2008092081A8 (en) Targeted delivery of sirna
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2013007763A9 (en) MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
WO2006119363A3 (en) Mutations in oas1 genes
WO2005054438A3 (en) Nucleic acid molecules containing recombination sites and methods of using the same
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2007100874A3 (en) Compositions containing peptides with non-natural amino acids and methods of use
WO2010001134A3 (en) Insulin fusion polypeptides
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
WO2005069855A3 (en) Modulators of angiogenesis
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06733652

Country of ref document: EP

Kind code of ref document: A2